checkAd

     132  0 Kommentare Medolife Rx Announces Positive Pre-Clinical Results Showing Up to 95 Percent Cancer Cell Apoptosis with Introduction of Lead Cancer Drug Candidate

    BURBANK, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today pre-clinical study results conducted at one of the leading cancer research centers in the United States showing that the Company’s lead drug candidate Escozine caused up to 95 percent Specific Induced Apoptosis (SIA) in various types of Leukemia cancer cells. Such a result is significant not only to the Company’s ongoing clinical research, but could have tremendous effects on cancer treatments worldwide.

    The study was broken into two objectives:

    1. to evaluate the effect of Escozine at four different concentration levels on the induction of apoptosis in five cancer cell lines: K-562: Human Chronic Myeloid Leukemia (CML); MEC-1: Human Chronic B Cell Leukemia; NAMALWA: Human Burkitt Lymphoma; RAJI: Human Burkitt Lymphoma, TP53 Wild Type; RAMOS: Human Burkitt Lymphoma, TP53 Mutated
    2. to evaluate the effect of Escozine at four different concentration levels on the induction of apoptosis in four Chronic Lymphocytic Leukemia (CLL) patients, two at high-risk and two at low-risk levels

    The result of the first objective was that cell death was observed in all cell lines when treated with Escozine after 48 hours of incubation. The effect on cell death was dependent on the concentration level of Escozine, with insignificant cell death being observed in concentration levels from 10-30 percent, a variation of cell death between 5-40 percent at a 50 percent concentration of Escozine, and a greater than 95 percent cell death in all cell lines when Escozine was included at 100 percent concentration, with the exception of RAMOS, which showed an approximate 50 percent cell death rate.

    In the second part of the study, cells were taken from four CLL human patients, two High Risk (HR) and two Low Risk (LR). The cells were introduced to Escozine at varying concentrations, and the results showed that both HR patients reported minimal effects at concentrations of 10 percent and 30 percent of Escozine; however, at concentrations of 50 percent, cell death occurred in approximately 50 percent of cells, and at 100 percent concentration levels, over 95 percent cell death was observed. In LR patients, similar results were observed with higher concentrations of Escozine at 50 percent and 100 percent inclusion where high levels of cell death were observed. The results were consistent with the cell line portion of the study, confirming that Escozine at higher concentrations can cause SIA, or cell death, in greater than 95 percent of cancer cells.

    Seite 1 von 4



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Medolife Rx Announces Positive Pre-Clinical Results Showing Up to 95 Percent Cancer Cell Apoptosis with Introduction of Lead Cancer Drug Candidate BURBANK, Calif., April 08, 2021 (GLOBE NEWSWIRE) - via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of …